Protocol Ledger

NCT06667076 · Phase II · RECRUITING

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small C

Interventional Phase II clinical trial protocol NCT06667076 sponsored by Johnson & Johnson / Janssen in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-16 Enrollment: 480 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06667076
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)480 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06667076
Protocol FieldVerified Registry Value
NCT IdentifierNCT06667076
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment480 participants (ESTIMATED)
Registered Start Date2024-12-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06667076
Hospital Research SiteLocationSite Profile
City of Hope National Medical CenterDuarte, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI